Johnson & Johnson Total Liabilities 2010-2024 | JNJ

Johnson & Johnson total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Johnson & Johnson total liabilities for the quarter ending March 31, 2024 were $98.784B, a 10.66% decline year-over-year.
  • Johnson & Johnson total liabilities for 2023 were $98.784B, a 10.66% decline from 2022.
  • Johnson & Johnson total liabilities for 2022 were $110.574B, a 2.39% increase from 2021.
  • Johnson & Johnson total liabilities for 2021 were $107.995B, a 3.24% decline from 2020.
Johnson & Johnson Annual Total Liabilities
(Millions of US $)
2023 $98,784
2022 $110,574
2021 $107,995
2020 $111,616
2019 $98,257
2018 $93,202
2017 $97,143
2016 $70,790
2015 $62,261
2014 $60,606
2013 $58,630
2012 $56,521
2011 $56,564
2010 $46,329
2009 $44,094
Johnson & Johnson Quarterly Total Liabilities
(Millions of US $)
2023-12-31 $98,784
2023-09-30 $94,833
2023-06-30 $115,277
2023-03-31 $125,100
2022-12-31 $110,574
2022-09-30 $100,525
2022-06-30 $101,367
2022-03-31 $103,646
2021-12-31 $107,995
2021-09-30 $108,956
2021-06-30 $106,860
2021-03-31 $106,723
2020-12-31 $111,616
2020-09-30 $106,220
2020-06-30 $95,402
2020-03-31 $93,723
2019-12-31 $98,257
2019-09-30 $97,311
2019-06-30 $94,332
2019-03-31 $91,072
2018-12-31 $93,202
2018-09-30 $91,077
2018-06-30 $92,476
2018-03-31 $93,370
2017-12-31 $97,143
2017-09-30 $81,679
2017-06-30 $80,885
2017-03-31 $74,577
2016-12-31 $70,790
2016-09-30 $67,600
2016-06-30 $67,341
2016-03-31 $63,584
2015-12-31 $62,261
2015-09-30 $61,712
2015-06-30 $60,905
2015-03-31 $60,712
2014-12-31 $60,606
2014-09-30 $55,506
2014-06-30 $57,152
2014-03-31 $56,748
2013-12-31 $58,630
2013-09-30 $57,129
2013-06-30 $54,660
2013-03-31 $54,681
2012-12-31 $56,521
2012-09-30 $55,190
2012-06-30 $55,316
2012-03-31 $54,828
2011-12-31 $56,564
2011-09-30 $50,294
2011-06-30 $49,982
2011-03-31 $48,287
2010-12-31 $46,329
2010-09-30 $40,956
2010-06-30 $39,449
2010-03-31 $40,527
2009-12-31 $44,094
2009-09-30 $41,174
2009-06-30 $41,191
2009-03-31 $42,309
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $360.407B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Merck (MRK) United States $321.391B 84.59
AbbVie (ABBV) United States $300.196B 15.26
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Sanofi (SNY) $120.637B 10.86
Innoviva (INVA) United States $0.959B 6.77